RecruitingPhase 4NCT06712407
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Calliditas Therapeutics AB
- Principal Investigator
- Krassimir MitchevCalliditas Therapeutics
- Intervention
- TARPEYO®(drug)
- Enrollment
- 60 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (30)
- Univ of Alabama/Birmingham, Birmingham, Alabama, United States
- Arizona Kidney Disease & Hypertension Centers (AKDHC), Glendale, Arizona, United States
- The Medical Research Group, Inc., Fresno, California, United States
- UCI Health-UCI Medical Center, Orange, California, United States
- Loma Linda University, San Bernardino, California, United States
- UCSF Health-UCSF Medical Center-Parnassus - Nephrology and Hypertension Faculty Practice, San Francisco, California, United States
- Stanford University, Stanford, California, United States
- University of Colorado Hospital (UCH) - Kidney Disease and Hypertension Clinic - Anschutz Medical Campus Location, Aurora, Colorado, United States
- Yale University Nephrology Clinical Trials Program, New Haven, Connecticut, United States
- Florida Kidney Physicians, Boca Raton, Florida, United States
- Central Florida Kidney Specialists, Orlando, Florida, United States
- Southeastern Clinical Research Institute, LLC, Augusta, Georgia, United States
- Cobb Nephrology Hypertension Associates, PC, Austell, Georgia, United States
- Georgia Nephrology, Lawrenceville, Georgia, United States
- University of Louisville, Louisville, Kentucky, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Worldwide Clinical Trials
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06712407 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital